share_log

HC Wainwright & Co. Initiates Coverage On Acurx Pharmaceuticals With Buy Rating, Announces Price Target of $14

HC Wainwright & Co. Initiates Coverage On Acurx Pharmaceuticals With Buy Rating, Announces Price Target of $14

HC 溫賴特 & 有限公司.通過購買評級啟動 Asurx 藥品的覆蓋範圍,宣布目標價為 14 美元
Benzinga Real-time News ·  2022/12/19 06:11

HC Wainwright & Co. analyst Ed Arce initiates coverage on Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy rating and announces Price Target of $14.

HC Wainwright&Co.分析師Ed Arce以買入評級啟動對Acurx製藥(納斯達克:ACXP)的報道,並宣佈目標價為14美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論